Current Affairs - Miscellaneous

Exercise : Miscellaneous - Latest Current Affairs
  • Miscellaneous - Latest Current Affairs
131.
According to the ICRA Ratings report, what is the projected GDP growth rate for India in the first quarter of fiscal year 2023 (FY24)?
8.5%
6.1%
7.0%
9.5%
Answer: Option
Explanation:
According to the ICRA Ratings report the projected GDP growth rate for India in the first quarter of FY24 is 8.5%.

132.
Which organization has partnered with IIT Bombay and the Shakti Sustainable Energy Foundation to promote innovation in the field of green hydrogen?
Reliance Industries
GAIL India
HSBC India
BHEL
Answer: Option
Explanation:
IIT Bombay and the Shakti Sustainable Energy Foundation have partnered with HSBC India to support technological advancements to make green hydrogen more efficient, cost-effective, and scalable. The partnership is backed by a grant of INR 15 crore (about $2 million).

133.
What is the theme of the B20 Summit India 2023?
Responsible, Accelerated, Innovative, Sustainable, Equitable (R.A.I.S.E) Businesses
Business Opportunities in India (B.O.I.N)
Bridging the Digital Divide
Global Economic Trends In Businesses (G.E.T.I.B)
Answer: Option
Explanation:
The theme of the B20 Summit India 2023 is Responsible, Accelerated, Innovative, Sustainable, Equitable (R.A.I.S.E) Businesses.

134.
Which life insurance company in India recently launched a dedicated 24x7 inbound contact centre for customer queries?
LIC (Life Insurance Corporation of India)
HDFC Life Insurance
ICICI Prudential Life Insurance
SBI Life Insurance
Answer: Option
Explanation:
SBI Life Insurance launched a dedicated contact centre and became the first private life insurance company in the country to have such extensive customer care support.

135.
What group of individuals was Abrysvo originally approved for before its expanded approval for infants?
Pregnant women
Adults aged 60 years and older
Children aged 2 to 12 years
Healthcare workers
Answer: Option
Explanation:
Abrysvo is designed to protect infants from birth to 6 months of age against lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV). Abrysvo was originally approved for adults aged 60 years and older to prevent LRTD caused by RSV.